This paper presents an overview of the literature on the treatment of arterial hypertension drugs that block the renin-angiotensin-aldosterone system (RAAS) – angiotensin receptor blockers ΙΙ (ARB), whose action is based on inhibition of the RAAS at the AII receptor. ARB candesartan (atakand), along with a strong long-term antihypertensive effect has organoprotective (causes regression of LVH has nephroprotection) antidiabetogennym effect, prevents the development of stroke. Clinical experience suggests candesartan, high efficiency and a good range of security among different categories of hypertensive patients with concomitant pathology, chronic heart failure, diabetes, obesity.

The review focuses on the main strategies of antihypertensive therapy set out in the 2018 ESC/ESH recommendations. The basis of antihypertensive therapy consists of five main classes of antihypertensive drugs, which should form the basis of the combined drug antihypertensive therapy in most patients. The single pill strategy is to take advantage of fixed combinations as a starting antihypertensive therapy for most patients. Among the fixed combinations, the combination of an ACE inhibitor with a diuretic (Noliprel®) remains one of the most preferred for antihypertensive therapy, since In addition to its antihypertensive potential, it has the ability to prevent renal, coronary complications and cerebrovascular events, to influence the progression of atherosclerosis, the occurrence of new cases of diabetes and to achieve a statistically significant reduction in total mortality

No abstract